Package Leaflet: Information for the User
Abiraterona Tronyl 500 mg film-coated tablets EFG
abiraterone acetate
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack
Abiraterona Tronyl contains the active substance abiraterone acetate. It is used for the treatment of prostate cancer in adult men that has spread to other parts of the body. Abiraterone acetate makes your body stop producing testosterone; this can slow down the growth of prostate cancer.
When abiraterone acetate is prescribed in the early stages of the disease and there is still a response to hormonal treatment, it is used together with treatment to reduce testosterone (androgen deprivation therapy).
When you take this medicine, your doctor will also prescribe another medicine called prednisone or prednisolone to reduce the risk of high blood pressure, fluid retention, or low potassium levels in your blood.
Do not take Abiraterona Tronyl
Do not take this medicine if any of the above applies to you. If you are unsure, consult your doctor or pharmacist before taking this medicine.
Warnings and precautions
Consult your doctor or pharmacist before starting to take abiraterone acetate:
Tell your doctor if you have been told you have any heart or blood vessel disorder, including heart rhythm problems (arrhythmia), or if you are being treated with medicines for these disorders.
Tell your doctor if you have yellowing of the skin or eyes, dark urine, or severe nausea or vomiting, as these may be signs or symptoms of liver problems. Rarely, liver failure (called acute hepatic failure) may occur, which can be life-threatening.
A decrease in the number of red blood cells, reduced sexual desire (libido), and cases of muscle weakness and/or muscle pain may occur.
Abiraterone acetate should not be taken in combination with Ra-223 due to a possible increased risk of bone fracture or death.
If you plan to take Ra-223 after treatment with abiraterone acetate and prednisone/prednisolone, you should wait 5 days before starting Ra-223 treatment.
If you are unsure if any of the above applies to you, consult your doctor or pharmacist before taking this medicine.
Blood tests
Abiraterone acetate may affect your liver even if you have no symptoms. While you are taking this medicine, your doctor will regularly perform blood tests to check for any effect on your liver.
Children and adolescents
This medicine should not be used in children or adolescents. If a child or adolescent accidentally ingests abiraterone acetate, they should go to the hospital immediately and bring this leaflet with them to show the emergency doctor.
Other medicines and Abiraterona Tronyl
Consult your doctor or pharmacist before using any medicine.
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines. This is important because abiraterone acetate may increase the effects of a number of medicines, including medicines for the heart, sedatives, some medicines for diabetes, herbal medicines (e.g., St. John's Wort), and others. Your doctor may consider changing the dose of these medicines. Additionally, some medicines may increase or decrease the effects of Abiraterona Tronyl. This may lead to side effects or Abiraterona Tronyl may not work as well as it should.
Androgen deprivation therapy may increase the risk of heart rhythm problems. Tell your doctor if you are being treated with medicines
Consult your doctor if you are taking any of the medicines listed above.
Abiraterona Tronyl with food
Pregnancy and breastfeeding
Abiraterone acetate is not indicated in women
Driving and using machines
It is unlikely that this medicine will affect your ability to drive or use tools or machines.
Abiraterona Tronyl contains lactose and sodium
Follow exactly the administration instructions of this medicine given by your doctor. If you are unsure, consult your doctor or pharmacist again.
The recommended dose is 1000 mg (two 500 mg tablets) once a day.
How to take this medicine
It is also possible that your doctor will prescribe other medicines while you are taking abiraterone acetate and prednisone or prednisolone.
If you take more Abiraterona Tronyl than you should
If you take more than you should, consult your doctor or go to the hospital immediately.
If you forget to take Abiraterona Tronyl
If you stop taking Abiraterona Tronyl
Do not stop taking abiraterone acetate or prednisone or prednisolone unless your doctor tells you to.
If you have any further questions on the use of this product, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Stop taking Abiraterona Tronyl and contact your doctor immediately if you experience any of the following:
Other side effects are:
Very common(may affect more than 1 in 10 people)
Common(may affect up to 1 in 10 people)
Uncommon(may affect up to 1 in 100 people)
Rare(may affect up to 1 in 1,000 people)
Not known(frequency cannot be estimated from the available data)
Bone density loss may occur in men receiving treatment for prostate cancer. Abiraterone acetate in combination with prednisone or prednisolone may increase this bone density loss.
Reporting of side effects
If you experience any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Spanish Pharmacovigilance System for Human Use Medicines: www.notificaRAM.es. By reporting side effects, you can help provide more information on the safety of this medicine.
This medicine does not require any special storage conditions.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and blister after EXP. The expiry date is the last day of the month shown.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help protect the environment.
Composition of Abiraterona Tronyl
Coating: polyvinyl alcohol, titanium dioxide (E171), macrogol 3350, talc, red iron oxide (E172), black iron oxide (E172).
Appearance and packaging
Abiraterona Tronyl tablets are purple, oval, biconvex, film-coated (21.1 mm in length x 9.6 mm in width)
Abiraterona Tronyl is available in packs of 56 or 60 film-coated tablets.
Not all pack sizes may be marketed.
Marketing authorisation holder
Laboratórios Basi - Indústria Farmacêutica, S.A.
Parque Industrial Manuel Lourenço Ferreira, Lote 15
3450-232 Mortágua, Portugal
Phone: +351 231 920 250
Fax: +351 231 921 055
Email: basi@basi.pt
Local representative
LAPHYSAN, S.A.U.
Anabel Segura 11, Edificio A, Planta 4, Puerta D,
28108 Alcobendas - Madrid
Spain
Manufacturer
Laboratórios Basi - Indústria Farmacêutica, S.A.
Parque Industrial Manuel Lourenço Ferreira, Lotes 8, 15 e 16
3450-232 Mortágua, Portugal
This medicine is authorised in the Member States of the European Economic Area under the following names:
Portugal:
Abiraterona Tronyl 500 mg film-coated tablets
Spain:
Abiraterona Tronyl 500 mg film-coated tablets
Date of last revision of this leaflet: 04/2024